Literature DB >> 21907194

The role of different VEGF isoforms in scar formation after glaucoma filtration surgery.

Tine Van Bergen1, Evelien Vandewalle, Sara Van de Veire, Mieke Dewerchin, Jean-Marie Stassen, Lieve Moons, Ingeborg Stalmans.   

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in both physiological and pathological angiogenesis. Our previous studies showed a differential role of VEGF isoforms in retinal physiological angiogenesis. We also demonstrated that non-selective inhibition of VEGF by bevacizumab had a beneficial effect on surgical outcome after glaucoma filtration surgery by reducing angiogenesis as well as fibrosis. However, the function of the VEGF isoforms in pathological angiogenesis and wound healing in the eye still remains unidentified. This study was designed to elucidate the differential roles of VEGF isoforms in scar formation after trabeculectomy. Furthermore, we also investigated whether pegaptanib (Macugen™, Pfizer), an aptamer which specifically blocks VEGF(165), could improve surgical outcome by reducing postoperative scarring. VEGF-R2 and neuropilin-1 (NRP-1) expression was analyzed in vitro by RT-PCR, and were found to be expressed at higher levels in human umbilical vein endothelial cells (HUVEC) as compared to Tenon fibroblasts (TF). The effect of the different VEGF isoforms (VEGF(121), VEGF(165) and VEGF(189)) and pegaptanib on cell proliferation was determined via WST-1 assay. Endothelial cell proliferation was stimulated after addition of VEGF(121) and VEGF(165), whereas VEGF(121) and VEGF(189) increased fibroblast growth. These effects on proliferation were associated with an activation of the ERK pathway, as revealed using the TransAM c-Myc assay. Inhibition of the ERK pathway, by PD98059 administration, significantly reduced VEGF isoform induced cell growth. A dose-dependent reduction of endothelial cell proliferation was observed after pegaptanib administration, while only the highest dose was able to inhibit fibroblast growth. Next, the in vivo effect of pegaptanib was investigated in a rabbit model of trabeculectomy. The surgical outcome was evaluated by performing clinical investigations (IOP, bleb area, height and survival), as well as histomorphometric analyses of angiogenesis (CD31), inflammation (CD45) and fibrosis (Sirius Red). A single postoperative application of pegaptanib had a beneficial impact on surgical outcome, mainly by reducing angiogenesis, but not inflammation or collagen deposition. Repeated injections slightly improved surgical outcome, but again solely by reducing angiogenesis. In summary, our results revealed that the VEGF isoforms play a differential role in ocular wound healing: VEGF(165) and VEGF(121) predominantly affect blood vessel growth, whereas VEGF(189) is rather involved in fibrosis, an important process in wound healing.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907194     DOI: 10.1016/j.exer.2011.08.016

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  28 in total

1.  Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts.

Authors:  Xuan Wang; Ya-Zhi Fan; Liang Yao; Jian-Ming Wang
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma.

Authors:  Sana' Muhsen; Javiera Compan; Tze Lai; Christoph Kranemann; Catherine Birt
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

3.  Comparison of the effect of mitomycin C and bevacizumab-methylcellulose mixture on combined phacoemulsification and non-penetrating deep sclerectomy surgery on the intraocular pressure (a clinical trial study).

Authors:  Ali Mostafaei; Nazli Taheri; Morteza Ghojazadeh; Atena Latifi; Neda Moghaddam
Journal:  Int Ophthalmol       Date:  2019-01-17       Impact factor: 2.031

Review 4.  Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.

Authors:  Megan Kim; Chelsea Lee; Rachael Payne; Beatrice Y J T Yue; Jin-Hong Chang; Hongyu Ying
Journal:  Surv Ophthalmol       Date:  2015-05-15       Impact factor: 6.048

5.  ZD6474 attenuates TGF-β1-induced fibrosis in human Tenon fibroblasts and inhibits neovascularization via AKT-mTOR signaling pathway.

Authors:  Wenting Liu; Yaying Chen; Xiangyuan Song; Yiwen Xue; Yuyan Zhang
Journal:  Int Ophthalmol       Date:  2022-10-13       Impact factor: 2.029

6.  Subconjunctival bevacizumab as an adjuvant in first-time filtration surgery for patients with primary glaucomas.

Authors:  Luis Gustavo Biteli; Tiago Santos Prata
Journal:  Int Ophthalmol       Date:  2013-02-07       Impact factor: 2.031

7.  Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery.

Authors:  Qian Han; Yuqi Wang; Xiabin Li; Ribo Peng; Ailing Li; Zhiyong Qian; Ling Yu
Journal:  J Mater Sci Mater Med       Date:  2015-08-19       Impact factor: 3.896

8.  Bevacizumab-loaded polyurethane subconjunctival implants: effects on experimental glaucoma filtration surgery.

Authors:  Jayter Silva Paula; Vanessa Raquel Coimbra Ribeiro; Fernando Chahud; Roberta Cannellini; Tassia Cristina Monteiro; Elionai Cassiana de Lima Gomes; Peter Sol Reinach; Maria de Lourdes Veronese Rodrigues; Armando Silva-Cunha
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-07       Impact factor: 2.671

9.  Effect of connective tissue growth factor gene editing using adeno-associated virus-mediated CRISPR-Cas9 on rabbit glaucoma filtering surgery outcomes.

Authors:  Eun Jung Lee; Jong Chul Han; Do Young Park; Junhun Cho; Changwon Kee
Journal:  Gene Ther       Date:  2020-06-15       Impact factor: 5.250

10.  Collecting and deactivating TGF-β1 hydrogel for anti-scarring therapy in post-glaucoma filtration surgery.

Authors:  Ruiqi Wang; Boyang Chen; Haiying Wei; Wei Yan; Yuping Wu; Cao Wang; Bosong Zhang; Fengzhen Liu; Hui Tian; Xiongbiao Chen; Weiming Tian
Journal:  Mater Today Bio       Date:  2022-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.